Proportion of patients who have no AOM recurrences at 12 months post‐randomisation
Grommets showed no clear difference in proportion of patients who have no AOM recurrences at 12 months… compared with active monitoring (low certainty).
1 finding from 1 review
Total number of AOM recurrences at 6 months post‐randomisation
Grommets showed no clear difference in total number of AOM recurrences at 6 months post‐randomisation compared with active monitoring (low certainty).
1 finding from 1 review
Total number of AOM recurrences at 12 months post‐randomisation
1 finding from 1 review
Disease‐specific quality of life
1 finding from 1 review
Depressive symptoms · family carers of people with dementia
1 finding from 1 review
Anxiety · family carers of people with dementia
1 finding from 1 review
Carer burden · family carers of people with dementia
1 finding from 1 review
Dropout · family carers of people with dementia
It is very uncertain whether MBSR changes dropout rates compared with active control (very low certainty).
1 finding from 1 review
Depressive symptoms · family carers of people with dementia
1 finding from 1 review
Anxiety · family carers of people with dementia
1 finding from 1 review
Carer burden · family carers of people with dementia
1 finding from 1 review
Dropout · family carers of people with dementia
It is very uncertain whether MBSR changes dropout rates compared with inactive control (very low certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
It is very uncertain whether cannabis cigarettes (115 mg THC) changes proportion of patients achieving clinical remission compared with placebo cigarettes (very low certainty).
1 finding from 1 review
CRP (mg/dL) at end of study · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · Patients with active Crohn's disease
It is very uncertain whether cannabis oil (5% cannabidiol sublingual oil) changes serious adverse events compared with placebo oil (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of patients achieving clinical response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found